[A22-76] Pembrolizumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2022
Commission awarded on 21.07.2022 by the Federal Joint Committee (G-BA).
Adult patients with advanced or recurrent microsatellite instability high or mismatch repair deficient endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.